Gibson Christopher
SEC CIK 1856369 · EDGAR
BoughtSold
Most active insiders at RXRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Borgeson Blake | Dir | — | $4.10M |
| 2 | Gibson Christopher | Dir | — | $3.84M |
| 3 | Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| 4 | Taylor Ben R | CFO | — | $157.7K |
| 5 | Bumpus Namandje | Dir | — | $28.1K |
| 6 | Michor Franziska | Dir | — | — |
| 7 | Hallett David | CSO | — | — |
| 8 | Dar Zavain | Dir | — | — |
| 9 | Li Dean Y | Dir | — | — |
| 10 | Sun Elaine D | Dir | — | — |
Transactions 305
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-05 17:03 | 2026-06-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 923.7K | +5% | $0 |
| DT | 2026-06-05 17:03 | 2026-06-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | S - Sale | $3.62 | -40.0K | 883.7K | -4% | -$144.8K |
| DT | 2026-05-27 16:15 | 2026-05-22 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 923.7K | +5% | $0 |
| DT | 2026-05-27 16:15 | 2026-05-22 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | S - Sale | $3.08 | -40.0K | 883.7K | -4% | -$123.2K |
| 2026-05-19 17:54 | 2026-05-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | F - Tax | $3.04 | -22.8K | 883.7K | -3% | -$69.4K | |
| DT | 2026-05-08 16:59 | 2026-05-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +60.0K | 966.6K | +7% | $0 |
| DT | 2026-05-08 16:59 | 2026-05-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | S - Sale | $3.37 | -40.0K | 926.6K | -4% | -$134.8K |
| DT | 2026-05-08 16:59 | 2026-05-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | G - Gift | $0.00 | -20.0K | 906.6K | -2% | $0 |
| DT | 2026-04-24 16:23 | 2026-04-22 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 946.6K | +4% | $0 |
| DT | 2026-04-24 16:23 | 2026-04-22 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | S - Sale | $3.61 | -40.0K | 906.6K | -4% | -$144.4K |
| D | 2026-04-10 16:05 | 2026-04-08 | PACB | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | Gibson Christopher | Dir | A - Grant | $0.00 | +57.5K | 111.4K | +107% | $0 |
| DT | 2026-04-08 16:58 | 2026-04-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 946.6K | +4% | $0 |
| DT | 2026-04-08 16:58 | 2026-04-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | S - Sale | $3.10 | -40.0K | 906.6K | -4% | -$124.0K |
| D | 2026-03-25 | 2026-03-23 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | S - Sale | $3.25 | -40.0K | 906.6K | -4% | -$130.0K |
| D | 2026-03-25 | 2026-03-23 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 946.6K | +4% | $0 |
| D | 2026-03-11 | 2026-03-09 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +20.0K | 926.6K | +2% | $0 |
| D | 2026-03-11 | 2026-03-09 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | G - Gift | $0.00 | -20.0K | 906.6K | -2% | $0 |
| D | 2026-03-05 | 2026-03-03 | PACB | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | Gibson Christopher | Dir | A - Grant | $0.00 | +53.9K | 53.9K | New | $0 |
| D | 2026-02-19 | 2026-02-19 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | S - Sale | $3.46 | -40.0K | 906.6K | -4% | -$138.4K |
| D | 2026-02-19 | 2026-02-19 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 946.6K | +4% | $0 |
| D | 2026-02-19 | 2026-02-17 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | F - Tax | $3.49 | -27.3K | 906.6K | -3% | -$95.2K |
| D | 2026-02-06 | 2026-02-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | S - Sale | $4.12 | -40.0K | 913.8K | -4% | -$164.8K |
| D | 2026-02-06 | 2026-02-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | A - Grant | $0.00 | +30.3K | 944.2K | +3% | $0 |
| D | 2026-02-06 | 2026-02-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | F - Tax | $3.56 | -10.4K | 933.8K | -1% | -$36.9K |
| D | 2026-02-06 | 2026-02-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 953.8K | +4% | $0 |
| D | 2026-01-22 | 2026-01-20 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +40.0K | 953.8K | +4% | $0 |
| D | 2026-01-22 | 2026-01-20 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | S - Sale | $4.47 | -40.0K | 913.8K | -4% | -$178.8K |
| D | 2026-01-07 | 2026-01-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | S - Sale | $4.25 | -40.0K | 933.8K | -4% | -$170.0K |
| D | 2026-01-07 | 2026-01-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | C - Cnv Deriv | $0.00 | +60.0K | 973.8K | +7% | $0 |
| D | 2026-01-07 | 2026-01-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Dir | G - Gift | $0.00 | -20.0K | 913.8K | -2% | $0 |
| D | 2025-12-19 | 2025-12-19 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $4.50 | -40.0K | 913.8K | -4% | -$180.0K |
| D | 2025-12-19 | 2025-12-19 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 953.8K | +4% | $0 |
| D | 2025-12-05 | 2025-12-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +60.0K | 973.8K | +7% | $0 |
| D | 2025-12-05 | 2025-12-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -20.0K | 913.8K | -2% | $0 |
| D | 2025-12-05 | 2025-12-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $4.63 | -40.0K | 933.8K | -4% | -$185.2K |
| D | 2025-11-19 | 2025-11-17 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $4.14 | -40.4K | 913.8K | -4% | -$167.2K |
| D | 2025-11-19 | 2025-11-19 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $4.16 | -40.0K | 913.8K | -4% | -$166.4K |
| D | 2025-11-19 | 2025-11-19 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 953.8K | +4% | $0 |
| D | 2025-11-06 | 2025-11-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $5.21 | -40.0K | 974.2K | -4% | -$208.4K |
| D | 2025-11-06 | 2025-11-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +60.0K | 1.01M | +6% | $0 |
| D | 2025-11-06 | 2025-11-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -20.0K | 954.2K | -2% | $0 |
| D | 2025-10-24 | 2025-10-23 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 1.05M | +10% | $0 |
| D | 2025-10-24 | 2025-10-23 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $5.70 | -100.0K | 954.2K | -9% | -$570.0K |
| D | 2025-10-10 | 2025-10-10 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -20.0K | 954.2K | -2% | $0 |
| D | 2025-10-10 | 2025-10-10 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +120.0K | 1.07M | +13% | $0 |
| D | 2025-10-10 | 2025-10-10 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $6.04 | -100.0K | 974.2K | -9% | -$604.0K |
| D | 2025-09-26 | 2025-09-25 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 1.05M | +10% | $0 |
| D | 2025-09-26 | 2025-09-25 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $4.76 | -100.0K | 954.2K | -9% | -$476.0K |
| D | 2025-09-12 | 2025-09-10 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +120.0K | 1.07M | +13% | $0 |
| D | 2025-09-12 | 2025-09-10 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -20.0K | 954.2K | -2% | $0 |
| D | 2025-09-12 | 2025-09-10 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $4.71 | -100.0K | 974.2K | -9% | -$471.0K |
| D | 2025-08-28 | 2025-08-26 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $4.84 | -100.0K | 954.2K | -9% | -$484.0K |
| D | 2025-08-28 | 2025-08-26 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 1.05M | +10% | $0 |
| 2025-08-19 | 2025-08-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $5.64 | -40.4K | 954.2K | -4% | -$227.8K | |
| D | 2025-08-13 | 2025-08-11 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +423.7K | 1.50M | +39% | $0 |
| D | 2025-08-13 | 2025-08-11 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $5.28 | -500.3K | 1.00M | -33% | -$2.64M |
| D | 2025-08-13 | 2025-08-11 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 994.6K | -1.0% | $0 |
| DMI | 2025-08-13 | 2025-08-11 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $5.28 | -117.9K | 0 | -100% | -$622.4K |
| DMI | 2025-08-13 | 2025-08-11 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +117.9K | 17.9K | New | $0 |
| 2025-05-19 | 2025-05-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $4.25 | -36.2K | 1.08M | -3% | -$153.8K | |
| 2025-03-28 | 2025-03-27 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $6.04 | -138.6K | 1.12M | -11% | -$837.0K | |
| DM | 2025-03-07 | 2025-03-05+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $6.47 | -40.0K | 1.26M | -3% | -$259.0K |
| DM | 2025-03-07 | 2025-03-05+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 1.28M | +3% | $0 |
| 2025-02-20 | 2025-02-18 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $10.64 | -17.1K | 1.26M | -1% | -$182.3K | |
| DM | 2025-02-07 | 2025-02-05+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 1.29M | +3% | $0 |
| DM | 2025-02-07 | 2025-02-05+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $7.90 | -40.0K | 1.27M | -3% | -$316.0K |
| DM | 2025-02-05 | 2025-02-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +542.1K | 1.28M | +74% | $0 |
| D | 2025-02-05 | 2025-02-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $7.25 | -5,569 | 1.27M | -0.4% | -$40.4K |
| DM | 2025-01-13 | 2025-01-08+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 756.6K | +6% | $0 |
| DM | 2025-01-13 | 2025-01-08+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $7.18 | -40.0K | 736.6K | -5% | -$287.2K |
| DM | 2024-12-06 | 2024-12-04+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 756.6K | +6% | $0 |
| DM | 2024-12-06 | 2024-12-04+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $7.14 | -40.0K | 736.6K | -5% | -$285.6K |
| 2024-11-19 | 2024-11-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $6.18 | -26.0K | 736.6K | -3% | -$160.8K | |
| DM | 2024-11-15 | 2024-11-13+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 782.7K | +5% | $0 |
| DM | 2024-11-15 | 2024-11-13+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $7.54 | -40.0K | 762.7K | -5% | -$301.8K |
| DM | 2024-10-04 | 2024-10-02+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $6.12 | -40.0K | 762.7K | -5% | -$244.8K |
| DM | 2024-10-04 | 2024-10-02+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 782.7K | +5% | $0 |
| DM | 2024-09-06 | 2024-09-04+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +40.0K | 782.7K | +5% | $0 |
| DM | 2024-09-06 | 2024-09-04+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $6.09 | -40.0K | 762.7K | -5% | -$243.6K |
| D | 2024-08-30 | 2024-08-30 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +5,000 | 762.7K | +0.7% | +$12.4K |
| D | 2024-08-29 | 2024-08-29 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +5,000 | 757.7K | +0.7% | +$12.4K |
| D | 2024-08-28 | 2024-08-28 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +5,000 | 752.7K | +0.7% | +$12.4K |
| D | 2024-08-27 | 2024-08-27 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +5,000 | 747.7K | +0.7% | +$12.4K |
| D | 2024-08-26 | 2024-08-26 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +5,000 | 742.7K | +0.7% | +$12.4K |
| D | 2024-08-23 | 2024-08-23 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +5,000 | 737.7K | +0.7% | +$12.4K |
| 2024-08-19 | 2024-08-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $6.69 | -26.1K | 732.7K | -3% | -$174.5K | |
| DM | 2024-08-09 | 2024-08-07+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +50.0K | 778.7K | +7% | $0 |
| DM | 2024-08-09 | 2024-08-07+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $6.86 | -50.0K | 758.7K | -6% | -$343.0K |
| DA | 2024-07-12 | 2024-06-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 908.7K | +12% | $0 |
| DM | 2024-07-12 | 2024-07-10+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $7.47 | -100.0K | 758.7K | -12% | -$747.5K |
| D | 2024-07-12 | 2024-07-10 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -25.0K | 758.7K | -3% | $0 |
| DM | 2024-07-12 | 2024-07-10+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 808.7K | +14% | $0 |
| D | 2024-06-07 | 2024-06-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 833.7K | +3% | $0 |
| D | 2024-06-07 | 2024-06-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -25.0K | 808.7K | -3% | $0 |
| DM | 2024-06-07 | 2024-06-05+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $8.71 | -100.0K | 708.7K | -12% | -$871.0K |
| 2024-05-17 | 2024-05-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $10.01 | -26.1K | 808.7K | -3% | -$261.1K | |
| DM | 2024-05-03 | 2024-05-01+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $8.10 | -100.0K | 834.8K | -11% | -$810.0K |
| D | 2024-05-03 | 2024-05-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +21.3K | 856.1K | +3% | $0 |
| D | 2024-05-03 | 2024-05-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -25.0K | 913.5K | -3% | $0 |
| D | 2024-04-05 | 2024-04-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -25.0K | 1.02M | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations